Overview of ФРИ-АЛ
ФРИ-АЛ: What is it?
| Property | Description |
|---|---|
| Active ingredient | Levocetirizine Dihydrochloride |
| Form | Film-coated tablets, Oral solution |
| Pharmacological class | Second-generation Antihistamine |
| General purpose | Relief from allergic symptoms |
| Origin | Synthetic (chemically derived) |
What Type of Medicine is ФРИ-АЛ?
ФРИ-АЛ is a medicinal product whose identity is established by the active ingredient, Levocetirizine Dihydrochloride. It is fundamentally classified as an anti-allergic agent, belonging to the second-generation antihistamine pharmacological class. It works by blocking a natural substance called histamine that the body produces during an allergic reaction, an action recognized for sustained efficacy.
Its specific therapeutic category is the highly selective Histamine H1-receptor antagonist. This modern class of antihistamines is designed for minimal blood-brain barrier penetration, a characteristic that distinguishes it from older compounds. This design provides the benefit of delivering sustained anti-allergic relief while reducing the risk of pronounced sedation, making it suitable for continuous daily use.
Composition and Origin: The Active Enantiomer
The core substance, Levocetirizine, is a chemically synthetic, single-component compound that represents a pharmaceutical refinement. Levocetirizine is the isolated, pharmacologically active R-enantiomer of Cetirizine. This specific form is responsible for the drug’s primary therapeutic activity, resulting in high potency.
This isolation process, known as a chiral switch, ensures the drug contains only the molecular structure responsible for nearly all of the compound's anti-allergic potency. ФРИ-АЛ is available as an oral dosage form, specifically manufactured as film-coated tablets and an oral solution, offering options for different patient groups.
What is the General Purpose of ФРИ-АЛ?
The general purpose of ФРИ-АЛ is to interrupt the allergic cascade by achieving a sustained blockade of the H1 receptors in the body. This is achieved through its high affinity for the target receptors.
This selective receptor blockade translates into the general benefits of suppressing both the initial and prolonged manifestations of an allergic reaction, such as those that characterize seasonal allergic discomfort. This provides relief that lasts for up to 24 hours, resulting in an anti-pruritic (anti-itch) effect and the control of fluid leakage associated with allergic inflammation (anti-exudative effect).
Regulatory References
